Skip to main content
. 2022 Sep 8;23(18):10412. doi: 10.3390/ijms231810412

Figure 3.

Figure 3

Application of IL-7 and IL-7R in cancer immunotherapy. (A) Recombinant IL-7 administration. (B) Combination use of IL-7. (C) CAR-T and TCR T cell expressed IL-7. (D) CAR-T expressing engineered IL-7R or C7R. (E) CTL expressed engineered IL-7R. (F) Anti-IL-7R monoclonal antibodies. (G) IL-7R pathway signaling inhibitors.